Lucitanib is a novel dual inhibitor that targets human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) and restricts the blood supply feeding the tumors. In this case, lucitanib blocks VEGFR 1-3 and FGFR1/2 kinases, leading to tumor cell death.
The LIO-1 study (NCT04042116) is examining the combination of lucitanib with the PD-1 inhibitor nivolumab across a range of solid tumor cancers. During the 2022 annual meeting of the American Society of Clinical Oncology, Manish R. Patel, MD, director of drug development at Florida Cancer Specialists/Sarah Cannon Research Institute in Sarasota, Florida, presented findings from the phase 1/2 dose escalation study evaluating lucitanib with nivolumab in advanced gynecological cancers, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC).
The following patients were enrolled: those with EC who had received at least 1 prior platinum-based chemotherapy; patients with CC who had received chemotherapy with or without bevacizumab; patients with high-grade OC who had received at least 2 prior chemotherapy lines; and those with EC or OC with clear-cell histology who had received at least 1 prior platinum-based chemotherapy plus taxane. Patients with prior PD-1 or PD-L1 therapy were excluded, except for 10 patients in the EC group.
Dosing. Patients started with 6 mg of lucitanib daily, escalating to 8 mg per day and then 10 mg per day if safety criteria were met, along with intravenous nivolumab 480 mg every 28 days. At the time of data cutoff, 31 of 124 patients were continuing in the study. Across cohorts, 32 (26%) patients escalated to the 8-mg dose and 20 (16%) escalated to the 10-mg dose. More patients continued in the CC cohort in phase 2 of the trial.
Results. Updated data presented in a poster showed responses as follows:
A confirmed overall response rate (ORR) was seen in 5 of 22 patients with EC (22.7%; 5 partial responses [PRs]).
12 of 46 responses were reported in patients with CC (26.1%; 2 complete responses [CRs], 10 PRs).
4 of 33 responses were reported in patients with OC (12.1%; 4 partial responses).
6 of 23 responses were reported in patients with EC/OC clear cell (21.7%; 1 CR, 5 PRs).
Response duration ranged from 1.9 to 13.1+ months in the CC cohort, 5.6 to 14.8+ months in the EC cohort, 3.7 to 14.9+ months in the OC cohort, and 3.5 to 10.4+ in the EC/OC clear cell cohort.
Of 5 patients with EC with prior PD-1 inhibitor treatment, 2 had PRs and 1 had stable disease of more than 7 months.
Across the cohorts, the median duration of lucitanib and/or nivolumab treatment was 3.7 months (range, < 0.1-17.5). At cutoff, 37 patients (30%) had remained on 1 or both therapies for at least 6 months. Of the 124 patients, 50 (40%) met the bar for dose escalation at cycle 2, 63 (51%) were ineligible, and 11 (9%) did not reach cycle 2.
Of the 124 total patients, 115 had treatment-emergent adverse events (TEAEs) related to the study; 44% were grade 3 or higher. The most common TEAE was hypertension. Of the group, 21 patients had a dose reduction in lucitanib and 14 patients had TEAEs related to lucitanib that led to discontinuation. Safety results were similar across tumor types. Investigators concluded that the combination of lucitanib and nivolumab in advanced gynecological malignancies “has a manageable safety profile through effective dose titration.”
Reference
Patel MR, Makker V, Oaknin A, et al. Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). J Clin Oncol. 2022;40(suppl 16):5517. doi:10.1200/JCO.2022.40.16_suppl.5517
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More